Diagnostic tests for the detection of human papillomavirus-associated cervical lesions / Miriam Reuschenbach and Magnus von Knebel Doeberitz
Current diagnostic approaches for primary cervical cancer screening, work-up of equivocal or positive screening results or follow- - up after treatment of precancerous lesions primarily rely on the morphologic interpretation of squamous epithelial cells (Pap cytology), - in some setting accompanied by the detection of human papillomavirus DNA and have largely contributed to remarkable reduction - of disease incidence in countries with implemented screening programs. However, these approaches are limited by a poor sensitivity and - reproducibility of Pap cytology and low specificity for high grade cervical intraepithelial neoplasia of HPV DNA detection assays. Early - detection might be improved by complementing or even replacing these tests by markers which are more directly related to molecular - events triggering HPV-induced carcinogenesis and thereby might deliver more accurate diagnostic performance. The delineation of molecular - changes which occur during different stages of HPV infections and the identification of changes which induce neoplastic alterations - allow for the detection of markers that specifically highlight the transforming stage of the infection where viral oncogenes are overexpressed - and therefore allow for a more specific diagnosis of lesions that require treatment. The evaluation of such markers in clinical - studies revealed that some indeed show an improved diagnostic performance compared to Pap cytology or HPV DNA tests only..
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2013 |
|---|---|
| Erschienen: |
2013 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:19 |
|---|---|
| Enthalten in: |
Current pharmaceutical design - 19(2013), 8, Seite 1358-1370 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Reuschenbach, Miriam, 1980- [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Alphapapillomavirus |
|---|
| Anmerkungen: |
Gesehen am 10.01.2022 |
|---|
| Umfang: |
13 |
|---|
| doi: |
10.2174/1381612811319080002 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
1785254790 |
|---|
| LEADER | 01000caa a2200265 4500 | ||
|---|---|---|---|
| 001 | 1785254790 | ||
| 003 | DE-627 | ||
| 005 | 20230426205603.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 220110s2013 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.2174/1381612811319080002 |2 doi | |
| 035 | |a (DE-627)1785254790 | ||
| 035 | |a (DE-599)KXP1785254790 | ||
| 035 | |a (OCoLC)1341436883 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rda | ||
| 041 | |a eng | ||
| 100 | 1 | |a Reuschenbach, Miriam |d 1980- |e verfasserin |0 (DE-588)13879734X |0 (DE-627)703109723 |0 (DE-576)309094054 |4 aut | |
| 245 | 1 | 0 | |a Diagnostic tests for the detection of human papillomavirus-associated cervical lesions |c Miriam Reuschenbach and Magnus von Knebel Doeberitz |
| 264 | 1 | |c 2013 | |
| 300 | |a 13 | ||
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Gesehen am 10.01.2022 | ||
| 520 | |a Current diagnostic approaches for primary cervical cancer screening, work-up of equivocal or positive screening results or follow- - up after treatment of precancerous lesions primarily rely on the morphologic interpretation of squamous epithelial cells (Pap cytology), - in some setting accompanied by the detection of human papillomavirus DNA and have largely contributed to remarkable reduction - of disease incidence in countries with implemented screening programs. However, these approaches are limited by a poor sensitivity and - reproducibility of Pap cytology and low specificity for high grade cervical intraepithelial neoplasia of HPV DNA detection assays. Early - detection might be improved by complementing or even replacing these tests by markers which are more directly related to molecular - events triggering HPV-induced carcinogenesis and thereby might deliver more accurate diagnostic performance. The delineation of molecular - changes which occur during different stages of HPV infections and the identification of changes which induce neoplastic alterations - allow for the detection of markers that specifically highlight the transforming stage of the infection where viral oncogenes are overexpressed - and therefore allow for a more specific diagnosis of lesions that require treatment. The evaluation of such markers in clinical - studies revealed that some indeed show an improved diagnostic performance compared to Pap cytology or HPV DNA tests only. | ||
| 650 | 4 | |a Alphapapillomavirus | |
| 650 | 4 | |a Chromosomal Instability | |
| 650 | 4 | |a DNA Methylation | |
| 650 | 4 | |a DNA, Viral | |
| 650 | 4 | |a Female | |
| 650 | 4 | |a Humans | |
| 650 | 4 | |a Reproducibility of Results | |
| 650 | 4 | |a S Phase | |
| 650 | 4 | |a Uterine Cervical Neoplasms | |
| 650 | 4 | |a Vaginal Smears | |
| 700 | 1 | |a Knebel Doeberitz, Magnus von |e verfasserin |0 (DE-588)1022165291 |0 (DE-627)71693289X |0 (DE-576)364934239 |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Current pharmaceutical design |d Hilversum : Bentham Science Publ., 2000 |g 19(2013), 8, Seite 1358-1370 |h Online-Ressource |w (DE-627)325051666 |w (DE-600)2034245-7 |w (DE-576)273880217 |x 1873-4286 |7 nnns |
| 773 | 1 | 8 | |g volume:19 |g year:2013 |g number:8 |g pages:1358-1370 |g extent:13 |
| 856 | 4 | 0 | |u https://doi.org/10.2174/1381612811319080002 |x Verlag |x Resolving-System |z lizenzpflichtig |3 Volltext |
| 856 | 4 | 0 | |u https://www.eurekaselect.com/article/48326 |x Verlag |z lizenzpflichtig |3 Volltext |
| 912 | |a GBV_USEFLAG_U | ||
| 912 | |a GBV_ILN_2013 | ||
| 912 | |a ISIL_DE-16-250 | ||
| 912 | |a SYSFLAG_1 | ||
| 912 | |a GBV_KXP | ||
| 912 | |a SSG-OLC-PHA | ||
| 912 | |a GBV_ILN_20 | ||
| 912 | |a GBV_ILN_22 | ||
| 912 | |a GBV_ILN_24 | ||
| 912 | |a GBV_ILN_31 | ||
| 912 | |a GBV_ILN_65 | ||
| 912 | |a GBV_ILN_69 | ||
| 912 | |a GBV_ILN_1200 | ||
| 912 | |a GBV_ILN_2001 | ||
| 912 | |a GBV_ILN_2003 | ||
| 912 | |a GBV_ILN_2005 | ||
| 912 | |a GBV_ILN_2010 | ||
| 912 | |a GBV_ILN_2011 | ||
| 912 | |a GBV_ILN_4035 | ||
| 912 | |a GBV_ILN_4112 | ||
| 912 | |a GBV_ILN_4125 | ||
| 912 | |a GBV_ILN_4305 | ||
| 912 | |a GBV_ILN_4306 | ||
| 936 | u | w | |d 19 |j 2013 |e 8 |h 1358-1370 |g 13 |
| 951 | |a AR | ||
| 952 | |d 19 |j 2013 |e 8 |h 1358-1370 |g 13 | ||
| 980 | |2 2013 |1 01 |x DE-16-250 |b 403219551X |c 00 |f --%%-- |d --%%-- |e --%%-- |j --%%-- |y l01 |z 10-01-22 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 00 |s s |a hd2013 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 01 |s s |0 (DE-627)1410508463 |a wissenschaftlicher Artikel (Zeitschrift) | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 02 |s s |a per_2 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 03 |s s |a s_13 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s p |0 (DE-627)1480454664 |a Reuschenbach, Miriam | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s k |0 (DE-627)1416741658 |a Pathologisches Institut | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 04 |s s |a pos_1 | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s p |0 (DE-627)1435319745 |a Knebel Doeberitz, Magnus von | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416741658 |a Pathologisches Institut | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s k |0 (DE-627)1416466967 |a Medizinische Fakultät Heidelberg | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |0 (DE-627)1410501914 |a Verfasser | ||
| 982 | |2 2013 |1 01 |x DE-16-250 |8 05 |s s |a pos_2 | ||